WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery
10 February 2020 - 7:05PM
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the
“
Company” or “
WPD”), a clinical
stage pharmaceutical company, is pleased to announce that its drug
candidate WP1066 was the subject of a scientific paper published in
2019 entitled "Immunological Reprogramming in the CNS Tumor
Microenvironment and Therapeutic Efficacy of Radiotherapy with
STAT3 Blockade” which found that drug candidate WP1066 is
potentially capable of immune reprogramming in Glioblastoma animal
models.
Currently in clinical trials at the University
of Texas, MD Anderson Cancer Center, WP1066 represents a new class
of drugs, which WPD identifies as “Immune/Transcription
Modulators”. WP1066 and related analogs have not only demonstrated
the ability to directly induce apoptosis (tumor cell death) but
also the ability to stimulate an immune response to tumors allowing
T-cells to attack tumor cells. These unique drug properties
are a result of WP1066’s ability to inhibit the activated form of
STAT3, (p-STAT3.
One of the key findings of the research is that
immune-competent mice treated with both radiation and WP1066
developed an immunological memory that enabled them to prevent
regrowth of the tumor after these tumor cells were reintroduced.
The result was the development of long-term survivors, leading to
an increase in overall survival in these models. Of note was that
mice with a compromised immune system did not show this effect. The
study was also showed the most robust immunological responses were
located in the CNS (Central Nervous System) tumor microenvironment
rather than peripheral non-tumor tissue. Importantly, the
study indicated that the combination of STAT3 inhibition with whole
brain radiotherapy had the capacity to enhance the therapeutic
effect against established tumors based on immunological
competence.
Mariusz Olejniczak, CEO of WPD
commented “The findings in the report by Dr. Martina Ott, of MD
Anderson Cancer Center in collaboration with Dr. Amy Heimberger
(the Principle Investigator of the current investigator-initiated
clinical of WP1066 for brain tumors) are very encouraging,
especially given the increasing focus on the potential of STAT3
inhibition for the treatment of cancer. Making any kind of
discovery in treating glioblastoma is exciting, and these findings
could have a significant impact on understanding the role of STAT3
inhibition, as well as help focus our continued development of
WP1066.”
About WPD Pharmaceuticals
WPD is a biotechnology research and development
company with a focus on oncology, namely research and development
of medicinal products involving biological compounds and small
molecules. WPD has 10 novel drug candidates with 4 that are
in clinical development stage. These drug candidates were
researched at institutions including MD Anderson Cancer Center,
Mayo Clinic and Emory University, and WPD currently has ongoing
collaborations with Wake Forest University and leading hospitals
and academic centers in Poland.
WPD has entered into license agreements with
Wake Forest University Health Sciences and sublicense agreements
with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc.,
respectively, each of which grant WPD an exclusive, royalty-bearing
sublicense to certain technologies of the licensor. Such agreements
provide WPD with certain research, development, manufacturing and
sales rights, among other things.
On Behalf of the Board
‘Mariusz Olejniczak’
Mariusz OlejniczakCEO, WDP Pharmaceuticals
Contact:
Investor RelationsEmail: investors@wpdpharmaceuticals.comTel:
604-428-7050Web: www.wpdpharmaceuticals.com
Cautionary Statements:
Investors are cautioned that, except as disclosed in the
Company’s CSE listing statement, prepared in accordance with the
policies of the CSE, any information released or received with
respect to the transaction may not be accurate or complete and
should not be relied upon. Trading in the securities of the Company
should be considered highly speculative.
Neither the Canadian Securities Exchange nor the
Investment Industry Regulatory Organization of Canada accepts
responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking
statements. Forward-looking statements are statements that
contemplate activities, events or developments that the Company
anticipates will or may occur in the future. Forward-looking
statements in this press release include that our findings could
have a significant impact on understanding the role of STAT3
inhibition and that WPD’s drugs could be developed into novel
treatments for cancer.. These forward-looking statements
reflect the Company’s current expectations based on information
currently available to management and are subject to a number of
risks and uncertainties that may cause outcomes to differ
materially from those projected. Factors which may prevent
the forward looking statement from being realized is that
competitors or others may successfully challenge a granted patent
and the patent could be rendered void; that we are unable to raise
sufficient funding for our research; that our drugs don’t provide
positive treatment, or if they do, the side effects are damaging;
competitors may develop better or cheaper drugs; and we may be
unable to obtain regulatory approval for any drugs we develop.
Readers should refer to the risk disclosure included from
time-to-time in the documents the Company files on SEDAR, available
at www.sedar.com. Although the Company believes that the
assumptions inherent in these forward-looking statements are
reasonable, they are not guarantees of future performance and,
accordingly, they should not be relied upon and there can be no
assurance that any of them will prove to be accurate.
Finally, these forward-looking statements are made as of the date
of this press release and the Company assumes no obligation to
update them except as required by applicable law.
WPD Pharmaceuticals (CSE:WBIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
WPD Pharmaceuticals (CSE:WBIO)
Historical Stock Chart
From Jul 2023 to Jul 2024